Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 36.2 USD -4.16% Market Closed
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Supernus Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Supernus Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Interest Income Expense
$13.2m
CAGR 3-Years
N/A
CAGR 5-Years
41%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Interest Income Expense
$745m
CAGR 3-Years
19%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Interest Income Expense
$859m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-16%
CAGR 10-Years
-11%
Eli Lilly and Co
NYSE:LLY
Interest Income Expense
-$426.9m
CAGR 3-Years
-100%
CAGR 5-Years
-12%
CAGR 10-Years
-36%

See Also

What is Supernus Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
13.2m USD

Based on the financial report for Sep 30, 2024, Supernus Pharmaceuticals Inc's Interest Income Expense amounts to 13.2m USD.

What is Supernus Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
41%

Over the last year, the Interest Income Expense growth was 67%.

Back to Top